{"id":"W4394896461","doi":"10.1177/17562864241243186","title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Chugai Pharmaceutical; Horizon Therapeutics; Genentech; Grifols; Mitsubishi Tanabe Pharma Corporation; Warszawski Uniwersytet Medyczny; CSL Behring; National Institute for Health and Care Research; Regeneron Pharmaceuticals; National Institutes of Health; UCB Pharma; Argenx; Cytokinetics; Japan Blood Products Organization; Union Chimique Belge; Alexion Pharmaceuticals; Patient-Centered Outcomes Research Institute; Biogen; Centers for Disease Control and Prevention; Muscular Dystrophy Association; Uniwersytet Warszawski; Momenta Pharmaceuticals; Sanofi; AstraZeneca; Myasthenia Gravis Foundation of America","keywords":"Medicine; Myasthenia gravis; Interim; Interim analysis; Open label; Term (time); Extension (predicate logic); Adverse effect; Clinical trial; Internal medicine; Law; Computer science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002465661,0.0002247902,0.000751859,0.0002492988,0.0000375228,0.00001711848,0.0002995781,0.00006286216,0.00004846365],"category_scores_gemma":[0.00003838968,0.0001181928,0.00007639141,0.001178181,0.0002996498,0.000103167,0.0001879328,0.0002657429,4.599416e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001100615,"about_ca_system_score_gemma":0.00002029912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002942948,"about_ca_topic_score_gemma":0.0002596849,"domain_scores_codex":[0.9981675,0.0002981884,0.0005379644,0.0004880023,0.0002856048,0.0002227012],"domain_scores_gemma":[0.9991699,0.0002014742,0.0001342958,0.0004099627,0.00003593638,0.0000484584],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.008794877,0.002670768,0.9211267,0.00005531693,0.000259818,0.00001674139,0.0007858392,0.0003224464,0.0001124513,0.0001949779,3.159077e-7,0.06565972],"study_design_scores_gemma":[0.009136248,0.00344543,0.9847581,0.0001222216,0.0005074994,0.000001826815,0.00008123776,0.001332275,0.000005617285,0.0004370494,0.00005166801,0.0001207635],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949515,0.003148553,0.000147719,0.0002535231,0.00006314321,0.001356263,0.00001164288,0.00001752102,0.00005006109],"genre_scores_gemma":[0.9990007,0.0005935708,0.00004900379,0.0002826691,0.000004387436,0.00002307526,0.00001449641,0.00001943324,0.00001269086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06553896,"threshold_uncertainty_score":0.4819763,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02397615723265628,"score_gpt":0.329973967553128,"score_spread":0.3059978103204717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}